CELL PROLIFERATION-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2164556, encodeId=8cfe216455686, content=Initial Submission需要几天呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Tue Oct 24 09:32:14 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161348, encodeId=60cd21613489e, content=想请问一下各位前辈，字数上限4000，是包括abstract、introduction、methods、results、discussion、conclusion一共不超过4000么？我看已发表的文章里也不止这个字数啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9445432257, createdName=ms6000000598189015, createdTime=Sat Oct 07 15:17:00 CST 2023, time=2023-10-07, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2126690, encodeId=7b6a2126690ae, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：4个月接收，速度还行。稿费贵了点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82618491364, createdName=ms5000000525855900, createdTime=Tue Apr 18 10:22:45 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2129213, encodeId=28b421292133a, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：各位朋友们请问该期刊对于wb实验数据的要求是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d118655417, createdName=ms8000001126979725, createdTime=Sat Apr 29 10:32:13 CST 2023, time=2023-04-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2097725, encodeId=4d75209e7251f, content=偏重的研究方向：细胞增殖 经验分享：分值高的二区杂志，6个审稿人给了一些不痛不痒的小意见，没有拒稿，但是被编辑给拒了，垃圾。转投了其他一区杂志，接受了，因祸得福, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:34:30 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237083, encodeId=4a0b123e083bd, content=2.25 投稿，不知为何，5月才开始外审， 6.3通知Major revision，6.20修回，7.14通知Minor revision，7.26 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Sun Aug 07 13:58:40 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145106, encodeId=955021451062a, content=偏重的研究方向：肿瘤基础研究;干细胞;肿瘤生物学 经验分享：外审5个月，4个小修，编辑拒稿。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a28115392, createdName=ms3000000199710851, createdTime=Tue Jun 27 22:54:13 CST 2023, time=2023-06-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118154, encodeId=430721181541e, content=2月15号投稿，现在3月7号，还在awaiting reviewer assignment，发邮件没回应，托人问了华西的副主编，说帮忙看下，3天了也没动静，正在考虑转投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61698567057, createdName=ms5000001252099123, createdTime=Tue Mar 07 17:36:16 CST 2023, time=2023-03-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2100638, encodeId=36b12100638d0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：想请教大家目前的版面费多少？感觉好贵啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c35607832, createdName=ms8000000829948764, createdTime=Tue Nov 15 12:10:51 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077306, encodeId=049510e7306a2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：2021.11.30刚刚接受，分享一下，祝愿大家都顺利吧。 9月初投稿，10月中旬收到major revison，4个审稿人，1个非常正面，其他3个每人差不多提了4-5个问题，相对偏正面，但是对abstract，introduction和discussion部分提出了较多质疑。返修时勤勤恳恳对每个问题都进行了详细的解释和回答，一时无解的也都尽量完整回复。返回去后，好像又送到了第一轮的审稿人那里，其中3个表示满意。11月底看到状态变成Awaiting Editor Decision 再是好像Awaiting EIC desision，然后好像过两天就接收了。 投文章真的太不容易了，这一篇之前被 Theranostics 、EBioMedicine 、Journal of Cellular and Molecular Medicine、iscience、journal of translational medicine都拒了。。。。。。所以最后有了着落非常欣慰！ 最后再次祝愿大家发文章顺利！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fd2128416, createdName=1501fc32e8m, createdTime=Mon Dec 06 11:48:42 CST 2021, time=2021-12-06, status=1, ipAttribution=)]

2023-10-24 雨念来自浙江省

Initial Submission需要几天呀

25 0

[GetPortalCommentsPageByObjectIdResponse(id=2164556, encodeId=8cfe216455686, content=Initial Submission需要几天呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Tue Oct 24 09:32:14 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161348, encodeId=60cd21613489e, content=想请问一下各位前辈，字数上限4000，是包括abstract、introduction、methods、results、discussion、conclusion一共不超过4000么？我看已发表的文章里也不止这个字数啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9445432257, createdName=ms6000000598189015, createdTime=Sat Oct 07 15:17:00 CST 2023, time=2023-10-07, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2126690, encodeId=7b6a2126690ae, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：4个月接收，速度还行。稿费贵了点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82618491364, createdName=ms5000000525855900, createdTime=Tue Apr 18 10:22:45 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2129213, encodeId=28b421292133a, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：各位朋友们请问该期刊对于wb实验数据的要求是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d118655417, createdName=ms8000001126979725, createdTime=Sat Apr 29 10:32:13 CST 2023, time=2023-04-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2097725, encodeId=4d75209e7251f, content=偏重的研究方向：细胞增殖 经验分享：分值高的二区杂志，6个审稿人给了一些不痛不痒的小意见，没有拒稿，但是被编辑给拒了，垃圾。转投了其他一区杂志，接受了，因祸得福, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:34:30 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237083, encodeId=4a0b123e083bd, content=2.25 投稿，不知为何，5月才开始外审， 6.3通知Major revision，6.20修回，7.14通知Minor revision，7.26 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Sun Aug 07 13:58:40 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145106, encodeId=955021451062a, content=偏重的研究方向：肿瘤基础研究;干细胞;肿瘤生物学 经验分享：外审5个月，4个小修，编辑拒稿。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a28115392, createdName=ms3000000199710851, createdTime=Tue Jun 27 22:54:13 CST 2023, time=2023-06-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118154, encodeId=430721181541e, content=2月15号投稿，现在3月7号，还在awaiting reviewer assignment，发邮件没回应，托人问了华西的副主编，说帮忙看下，3天了也没动静，正在考虑转投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61698567057, createdName=ms5000001252099123, createdTime=Tue Mar 07 17:36:16 CST 2023, time=2023-03-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2100638, encodeId=36b12100638d0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：想请教大家目前的版面费多少？感觉好贵啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c35607832, createdName=ms8000000829948764, createdTime=Tue Nov 15 12:10:51 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077306, encodeId=049510e7306a2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：2021.11.30刚刚接受，分享一下，祝愿大家都顺利吧。 9月初投稿，10月中旬收到major revison，4个审稿人，1个非常正面，其他3个每人差不多提了4-5个问题，相对偏正面，但是对abstract，introduction和discussion部分提出了较多质疑。返修时勤勤恳恳对每个问题都进行了详细的解释和回答，一时无解的也都尽量完整回复。返回去后，好像又送到了第一轮的审稿人那里，其中3个表示满意。11月底看到状态变成Awaiting Editor Decision 再是好像Awaiting EIC desision，然后好像过两天就接收了。 投文章真的太不容易了，这一篇之前被 Theranostics 、EBioMedicine 、Journal of Cellular and Molecular Medicine、iscience、journal of translational medicine都拒了。。。。。。所以最后有了着落非常欣慰！ 最后再次祝愿大家发文章顺利！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fd2128416, createdName=1501fc32e8m, createdTime=Mon Dec 06 11:48:42 CST 2021, time=2021-12-06, status=1, ipAttribution=)]

2023-10-07 ms6000000598189015 来自黑龙江省

想请问一下各位前辈，字数上限4000，是包括abstract、introduction、methods、results、discussion、conclusion一共不超过4000么？我看已发表的文章里也不止这个字数啊。。。。。

34 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2164556, encodeId=8cfe216455686, content=Initial Submission需要几天呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Tue Oct 24 09:32:14 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161348, encodeId=60cd21613489e, content=想请问一下各位前辈，字数上限4000，是包括abstract、introduction、methods、results、discussion、conclusion一共不超过4000么？我看已发表的文章里也不止这个字数啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9445432257, createdName=ms6000000598189015, createdTime=Sat Oct 07 15:17:00 CST 2023, time=2023-10-07, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2126690, encodeId=7b6a2126690ae, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：4个月接收，速度还行。稿费贵了点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82618491364, createdName=ms5000000525855900, createdTime=Tue Apr 18 10:22:45 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2129213, encodeId=28b421292133a, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：各位朋友们请问该期刊对于wb实验数据的要求是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d118655417, createdName=ms8000001126979725, createdTime=Sat Apr 29 10:32:13 CST 2023, time=2023-04-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2097725, encodeId=4d75209e7251f, content=偏重的研究方向：细胞增殖 经验分享：分值高的二区杂志，6个审稿人给了一些不痛不痒的小意见，没有拒稿，但是被编辑给拒了，垃圾。转投了其他一区杂志，接受了，因祸得福, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:34:30 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237083, encodeId=4a0b123e083bd, content=2.25 投稿，不知为何，5月才开始外审， 6.3通知Major revision，6.20修回，7.14通知Minor revision，7.26 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Sun Aug 07 13:58:40 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145106, encodeId=955021451062a, content=偏重的研究方向：肿瘤基础研究;干细胞;肿瘤生物学 经验分享：外审5个月，4个小修，编辑拒稿。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a28115392, createdName=ms3000000199710851, createdTime=Tue Jun 27 22:54:13 CST 2023, time=2023-06-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118154, encodeId=430721181541e, content=2月15号投稿，现在3月7号，还在awaiting reviewer assignment，发邮件没回应，托人问了华西的副主编，说帮忙看下，3天了也没动静，正在考虑转投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61698567057, createdName=ms5000001252099123, createdTime=Tue Mar 07 17:36:16 CST 2023, time=2023-03-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2100638, encodeId=36b12100638d0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：想请教大家目前的版面费多少？感觉好贵啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c35607832, createdName=ms8000000829948764, createdTime=Tue Nov 15 12:10:51 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077306, encodeId=049510e7306a2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：2021.11.30刚刚接受，分享一下，祝愿大家都顺利吧。 9月初投稿，10月中旬收到major revison，4个审稿人，1个非常正面，其他3个每人差不多提了4-5个问题，相对偏正面，但是对abstract，introduction和discussion部分提出了较多质疑。返修时勤勤恳恳对每个问题都进行了详细的解释和回答，一时无解的也都尽量完整回复。返回去后，好像又送到了第一轮的审稿人那里，其中3个表示满意。11月底看到状态变成Awaiting Editor Decision 再是好像Awaiting EIC desision，然后好像过两天就接收了。 投文章真的太不容易了，这一篇之前被 Theranostics 、EBioMedicine 、Journal of Cellular and Molecular Medicine、iscience、journal of translational medicine都拒了。。。。。。所以最后有了着落非常欣慰！ 最后再次祝愿大家发文章顺利！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fd2128416, createdName=1501fc32e8m, createdTime=Mon Dec 06 11:48:42 CST 2021, time=2021-12-06, status=1, ipAttribution=)]

2023-04-18 ms5000000525855900 来自江苏省

审稿速度:6.0 | 投稿命中率:75.0
经验分享：4个月接收，速度还行。稿费贵了点

42 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2164556, encodeId=8cfe216455686, content=Initial Submission需要几天呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Tue Oct 24 09:32:14 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161348, encodeId=60cd21613489e, content=想请问一下各位前辈，字数上限4000，是包括abstract、introduction、methods、results、discussion、conclusion一共不超过4000么？我看已发表的文章里也不止这个字数啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9445432257, createdName=ms6000000598189015, createdTime=Sat Oct 07 15:17:00 CST 2023, time=2023-10-07, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2126690, encodeId=7b6a2126690ae, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：4个月接收，速度还行。稿费贵了点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82618491364, createdName=ms5000000525855900, createdTime=Tue Apr 18 10:22:45 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2129213, encodeId=28b421292133a, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：各位朋友们请问该期刊对于wb实验数据的要求是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d118655417, createdName=ms8000001126979725, createdTime=Sat Apr 29 10:32:13 CST 2023, time=2023-04-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2097725, encodeId=4d75209e7251f, content=偏重的研究方向：细胞增殖 经验分享：分值高的二区杂志，6个审稿人给了一些不痛不痒的小意见，没有拒稿，但是被编辑给拒了，垃圾。转投了其他一区杂志，接受了，因祸得福, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:34:30 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237083, encodeId=4a0b123e083bd, content=2.25 投稿，不知为何，5月才开始外审， 6.3通知Major revision，6.20修回，7.14通知Minor revision，7.26 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Sun Aug 07 13:58:40 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145106, encodeId=955021451062a, content=偏重的研究方向：肿瘤基础研究;干细胞;肿瘤生物学 经验分享：外审5个月，4个小修，编辑拒稿。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a28115392, createdName=ms3000000199710851, createdTime=Tue Jun 27 22:54:13 CST 2023, time=2023-06-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118154, encodeId=430721181541e, content=2月15号投稿，现在3月7号，还在awaiting reviewer assignment，发邮件没回应，托人问了华西的副主编，说帮忙看下，3天了也没动静，正在考虑转投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61698567057, createdName=ms5000001252099123, createdTime=Tue Mar 07 17:36:16 CST 2023, time=2023-03-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2100638, encodeId=36b12100638d0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：想请教大家目前的版面费多少？感觉好贵啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c35607832, createdName=ms8000000829948764, createdTime=Tue Nov 15 12:10:51 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077306, encodeId=049510e7306a2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：2021.11.30刚刚接受，分享一下，祝愿大家都顺利吧。 9月初投稿，10月中旬收到major revison，4个审稿人，1个非常正面，其他3个每人差不多提了4-5个问题，相对偏正面，但是对abstract，introduction和discussion部分提出了较多质疑。返修时勤勤恳恳对每个问题都进行了详细的解释和回答，一时无解的也都尽量完整回复。返回去后，好像又送到了第一轮的审稿人那里，其中3个表示满意。11月底看到状态变成Awaiting Editor Decision 再是好像Awaiting EIC desision，然后好像过两天就接收了。 投文章真的太不容易了，这一篇之前被 Theranostics 、EBioMedicine 、Journal of Cellular and Molecular Medicine、iscience、journal of translational medicine都拒了。。。。。。所以最后有了着落非常欣慰！ 最后再次祝愿大家发文章顺利！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fd2128416, createdName=1501fc32e8m, createdTime=Mon Dec 06 11:48:42 CST 2021, time=2021-12-06, status=1, ipAttribution=)]

2023-04-29 ms8000001126979725 来自湖北省

审稿速度:1.0 | 投稿命中率:50.0
经验分享：各位朋友们请问该期刊对于wb实验数据的要求是怎样的？

51 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2164556, encodeId=8cfe216455686, content=Initial Submission需要几天呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Tue Oct 24 09:32:14 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161348, encodeId=60cd21613489e, content=想请问一下各位前辈，字数上限4000，是包括abstract、introduction、methods、results、discussion、conclusion一共不超过4000么？我看已发表的文章里也不止这个字数啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9445432257, createdName=ms6000000598189015, createdTime=Sat Oct 07 15:17:00 CST 2023, time=2023-10-07, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2126690, encodeId=7b6a2126690ae, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：4个月接收，速度还行。稿费贵了点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82618491364, createdName=ms5000000525855900, createdTime=Tue Apr 18 10:22:45 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2129213, encodeId=28b421292133a, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：各位朋友们请问该期刊对于wb实验数据的要求是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d118655417, createdName=ms8000001126979725, createdTime=Sat Apr 29 10:32:13 CST 2023, time=2023-04-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2097725, encodeId=4d75209e7251f, content=偏重的研究方向：细胞增殖 经验分享：分值高的二区杂志，6个审稿人给了一些不痛不痒的小意见，没有拒稿，但是被编辑给拒了，垃圾。转投了其他一区杂志，接受了，因祸得福, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:34:30 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237083, encodeId=4a0b123e083bd, content=2.25 投稿，不知为何，5月才开始外审， 6.3通知Major revision，6.20修回，7.14通知Minor revision，7.26 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Sun Aug 07 13:58:40 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145106, encodeId=955021451062a, content=偏重的研究方向：肿瘤基础研究;干细胞;肿瘤生物学 经验分享：外审5个月，4个小修，编辑拒稿。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a28115392, createdName=ms3000000199710851, createdTime=Tue Jun 27 22:54:13 CST 2023, time=2023-06-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118154, encodeId=430721181541e, content=2月15号投稿，现在3月7号，还在awaiting reviewer assignment，发邮件没回应，托人问了华西的副主编，说帮忙看下，3天了也没动静，正在考虑转投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61698567057, createdName=ms5000001252099123, createdTime=Tue Mar 07 17:36:16 CST 2023, time=2023-03-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2100638, encodeId=36b12100638d0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：想请教大家目前的版面费多少？感觉好贵啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c35607832, createdName=ms8000000829948764, createdTime=Tue Nov 15 12:10:51 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077306, encodeId=049510e7306a2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：2021.11.30刚刚接受，分享一下，祝愿大家都顺利吧。 9月初投稿，10月中旬收到major revison，4个审稿人，1个非常正面，其他3个每人差不多提了4-5个问题，相对偏正面，但是对abstract，introduction和discussion部分提出了较多质疑。返修时勤勤恳恳对每个问题都进行了详细的解释和回答，一时无解的也都尽量完整回复。返回去后，好像又送到了第一轮的审稿人那里，其中3个表示满意。11月底看到状态变成Awaiting Editor Decision 再是好像Awaiting EIC desision，然后好像过两天就接收了。 投文章真的太不容易了，这一篇之前被 Theranostics 、EBioMedicine 、Journal of Cellular and Molecular Medicine、iscience、journal of translational medicine都拒了。。。。。。所以最后有了着落非常欣慰！ 最后再次祝愿大家发文章顺利！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fd2128416, createdName=1501fc32e8m, createdTime=Mon Dec 06 11:48:42 CST 2021, time=2021-12-06, status=1, ipAttribution=)]

2022-11-01 ms6000000988225388

偏重的研究方向：细胞增殖
经验分享：分值高的二区杂志，6个审稿人给了一些不痛不痒的小意见，没有拒稿，但是被编辑给拒了，垃圾。转投了其他一区杂志，接受了，因祸得福

59 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2164556, encodeId=8cfe216455686, content=Initial Submission需要几天呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Tue Oct 24 09:32:14 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161348, encodeId=60cd21613489e, content=想请问一下各位前辈，字数上限4000，是包括abstract、introduction、methods、results、discussion、conclusion一共不超过4000么？我看已发表的文章里也不止这个字数啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9445432257, createdName=ms6000000598189015, createdTime=Sat Oct 07 15:17:00 CST 2023, time=2023-10-07, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2126690, encodeId=7b6a2126690ae, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：4个月接收，速度还行。稿费贵了点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82618491364, createdName=ms5000000525855900, createdTime=Tue Apr 18 10:22:45 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2129213, encodeId=28b421292133a, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：各位朋友们请问该期刊对于wb实验数据的要求是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d118655417, createdName=ms8000001126979725, createdTime=Sat Apr 29 10:32:13 CST 2023, time=2023-04-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2097725, encodeId=4d75209e7251f, content=偏重的研究方向：细胞增殖 经验分享：分值高的二区杂志，6个审稿人给了一些不痛不痒的小意见，没有拒稿，但是被编辑给拒了，垃圾。转投了其他一区杂志，接受了，因祸得福, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:34:30 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237083, encodeId=4a0b123e083bd, content=2.25 投稿，不知为何，5月才开始外审， 6.3通知Major revision，6.20修回，7.14通知Minor revision，7.26 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Sun Aug 07 13:58:40 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145106, encodeId=955021451062a, content=偏重的研究方向：肿瘤基础研究;干细胞;肿瘤生物学 经验分享：外审5个月，4个小修，编辑拒稿。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a28115392, createdName=ms3000000199710851, createdTime=Tue Jun 27 22:54:13 CST 2023, time=2023-06-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118154, encodeId=430721181541e, content=2月15号投稿，现在3月7号，还在awaiting reviewer assignment，发邮件没回应，托人问了华西的副主编，说帮忙看下，3天了也没动静，正在考虑转投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61698567057, createdName=ms5000001252099123, createdTime=Tue Mar 07 17:36:16 CST 2023, time=2023-03-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2100638, encodeId=36b12100638d0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：想请教大家目前的版面费多少？感觉好贵啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c35607832, createdName=ms8000000829948764, createdTime=Tue Nov 15 12:10:51 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077306, encodeId=049510e7306a2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：2021.11.30刚刚接受，分享一下，祝愿大家都顺利吧。 9月初投稿，10月中旬收到major revison，4个审稿人，1个非常正面，其他3个每人差不多提了4-5个问题，相对偏正面，但是对abstract，introduction和discussion部分提出了较多质疑。返修时勤勤恳恳对每个问题都进行了详细的解释和回答，一时无解的也都尽量完整回复。返回去后，好像又送到了第一轮的审稿人那里，其中3个表示满意。11月底看到状态变成Awaiting Editor Decision 再是好像Awaiting EIC desision，然后好像过两天就接收了。 投文章真的太不容易了，这一篇之前被 Theranostics 、EBioMedicine 、Journal of Cellular and Molecular Medicine、iscience、journal of translational medicine都拒了。。。。。。所以最后有了着落非常欣慰！ 最后再次祝愿大家发文章顺利！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fd2128416, createdName=1501fc32e8m, createdTime=Mon Dec 06 11:48:42 CST 2021, time=2021-12-06, status=1, ipAttribution=)]

2022-08-07 COCO-么么哒

2.25 投稿，不知为何，5月才开始外审， 6.3通知Major revision，6.20修回，7.14通知Minor revision，7.26 Accept

66 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2164556, encodeId=8cfe216455686, content=Initial Submission需要几天呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Tue Oct 24 09:32:14 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161348, encodeId=60cd21613489e, content=想请问一下各位前辈，字数上限4000，是包括abstract、introduction、methods、results、discussion、conclusion一共不超过4000么？我看已发表的文章里也不止这个字数啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9445432257, createdName=ms6000000598189015, createdTime=Sat Oct 07 15:17:00 CST 2023, time=2023-10-07, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2126690, encodeId=7b6a2126690ae, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：4个月接收，速度还行。稿费贵了点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82618491364, createdName=ms5000000525855900, createdTime=Tue Apr 18 10:22:45 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2129213, encodeId=28b421292133a, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：各位朋友们请问该期刊对于wb实验数据的要求是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d118655417, createdName=ms8000001126979725, createdTime=Sat Apr 29 10:32:13 CST 2023, time=2023-04-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2097725, encodeId=4d75209e7251f, content=偏重的研究方向：细胞增殖 经验分享：分值高的二区杂志，6个审稿人给了一些不痛不痒的小意见，没有拒稿，但是被编辑给拒了，垃圾。转投了其他一区杂志，接受了，因祸得福, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:34:30 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237083, encodeId=4a0b123e083bd, content=2.25 投稿，不知为何，5月才开始外审， 6.3通知Major revision，6.20修回，7.14通知Minor revision，7.26 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Sun Aug 07 13:58:40 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145106, encodeId=955021451062a, content=偏重的研究方向：肿瘤基础研究;干细胞;肿瘤生物学 经验分享：外审5个月，4个小修，编辑拒稿。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a28115392, createdName=ms3000000199710851, createdTime=Tue Jun 27 22:54:13 CST 2023, time=2023-06-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118154, encodeId=430721181541e, content=2月15号投稿，现在3月7号，还在awaiting reviewer assignment，发邮件没回应，托人问了华西的副主编，说帮忙看下，3天了也没动静，正在考虑转投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61698567057, createdName=ms5000001252099123, createdTime=Tue Mar 07 17:36:16 CST 2023, time=2023-03-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2100638, encodeId=36b12100638d0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：想请教大家目前的版面费多少？感觉好贵啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c35607832, createdName=ms8000000829948764, createdTime=Tue Nov 15 12:10:51 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077306, encodeId=049510e7306a2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：2021.11.30刚刚接受，分享一下，祝愿大家都顺利吧。 9月初投稿，10月中旬收到major revison，4个审稿人，1个非常正面，其他3个每人差不多提了4-5个问题，相对偏正面，但是对abstract，introduction和discussion部分提出了较多质疑。返修时勤勤恳恳对每个问题都进行了详细的解释和回答，一时无解的也都尽量完整回复。返回去后，好像又送到了第一轮的审稿人那里，其中3个表示满意。11月底看到状态变成Awaiting Editor Decision 再是好像Awaiting EIC desision，然后好像过两天就接收了。 投文章真的太不容易了，这一篇之前被 Theranostics 、EBioMedicine 、Journal of Cellular and Molecular Medicine、iscience、journal of translational medicine都拒了。。。。。。所以最后有了着落非常欣慰！ 最后再次祝愿大家发文章顺利！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fd2128416, createdName=1501fc32e8m, createdTime=Mon Dec 06 11:48:42 CST 2021, time=2021-12-06, status=1, ipAttribution=)]

2023-06-27 ms3000000199710851 来自浙江省

偏重的研究方向：肿瘤基础研究;干细胞;肿瘤生物学
经验分享：外审5个月，4个小修，编辑拒稿。。。

36 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2164556, encodeId=8cfe216455686, content=Initial Submission需要几天呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Tue Oct 24 09:32:14 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161348, encodeId=60cd21613489e, content=想请问一下各位前辈，字数上限4000，是包括abstract、introduction、methods、results、discussion、conclusion一共不超过4000么？我看已发表的文章里也不止这个字数啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9445432257, createdName=ms6000000598189015, createdTime=Sat Oct 07 15:17:00 CST 2023, time=2023-10-07, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2126690, encodeId=7b6a2126690ae, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：4个月接收，速度还行。稿费贵了点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82618491364, createdName=ms5000000525855900, createdTime=Tue Apr 18 10:22:45 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2129213, encodeId=28b421292133a, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：各位朋友们请问该期刊对于wb实验数据的要求是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d118655417, createdName=ms8000001126979725, createdTime=Sat Apr 29 10:32:13 CST 2023, time=2023-04-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2097725, encodeId=4d75209e7251f, content=偏重的研究方向：细胞增殖 经验分享：分值高的二区杂志，6个审稿人给了一些不痛不痒的小意见，没有拒稿，但是被编辑给拒了，垃圾。转投了其他一区杂志，接受了，因祸得福, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:34:30 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237083, encodeId=4a0b123e083bd, content=2.25 投稿，不知为何，5月才开始外审， 6.3通知Major revision，6.20修回，7.14通知Minor revision，7.26 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Sun Aug 07 13:58:40 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145106, encodeId=955021451062a, content=偏重的研究方向：肿瘤基础研究;干细胞;肿瘤生物学 经验分享：外审5个月，4个小修，编辑拒稿。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a28115392, createdName=ms3000000199710851, createdTime=Tue Jun 27 22:54:13 CST 2023, time=2023-06-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118154, encodeId=430721181541e, content=2月15号投稿，现在3月7号，还在awaiting reviewer assignment，发邮件没回应，托人问了华西的副主编，说帮忙看下，3天了也没动静，正在考虑转投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61698567057, createdName=ms5000001252099123, createdTime=Tue Mar 07 17:36:16 CST 2023, time=2023-03-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2100638, encodeId=36b12100638d0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：想请教大家目前的版面费多少？感觉好贵啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c35607832, createdName=ms8000000829948764, createdTime=Tue Nov 15 12:10:51 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077306, encodeId=049510e7306a2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：2021.11.30刚刚接受，分享一下，祝愿大家都顺利吧。 9月初投稿，10月中旬收到major revison，4个审稿人，1个非常正面，其他3个每人差不多提了4-5个问题，相对偏正面，但是对abstract，introduction和discussion部分提出了较多质疑。返修时勤勤恳恳对每个问题都进行了详细的解释和回答，一时无解的也都尽量完整回复。返回去后，好像又送到了第一轮的审稿人那里，其中3个表示满意。11月底看到状态变成Awaiting Editor Decision 再是好像Awaiting EIC desision，然后好像过两天就接收了。 投文章真的太不容易了，这一篇之前被 Theranostics 、EBioMedicine 、Journal of Cellular and Molecular Medicine、iscience、journal of translational medicine都拒了。。。。。。所以最后有了着落非常欣慰！ 最后再次祝愿大家发文章顺利！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fd2128416, createdName=1501fc32e8m, createdTime=Mon Dec 06 11:48:42 CST 2021, time=2021-12-06, status=1, ipAttribution=)]

2023-03-07 ms5000001252099123 来自浙江省

2月15号投稿，现在3月7号，还在awaiting reviewer assignment，发邮件没回应，托人问了华西的副主编，说帮忙看下，3天了也没动静，正在考虑转投

46 0

[GetPortalCommentsPageByObjectIdResponse(id=2164556, encodeId=8cfe216455686, content=Initial Submission需要几天呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Tue Oct 24 09:32:14 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161348, encodeId=60cd21613489e, content=想请问一下各位前辈，字数上限4000，是包括abstract、introduction、methods、results、discussion、conclusion一共不超过4000么？我看已发表的文章里也不止这个字数啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9445432257, createdName=ms6000000598189015, createdTime=Sat Oct 07 15:17:00 CST 2023, time=2023-10-07, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2126690, encodeId=7b6a2126690ae, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：4个月接收，速度还行。稿费贵了点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82618491364, createdName=ms5000000525855900, createdTime=Tue Apr 18 10:22:45 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2129213, encodeId=28b421292133a, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：各位朋友们请问该期刊对于wb实验数据的要求是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d118655417, createdName=ms8000001126979725, createdTime=Sat Apr 29 10:32:13 CST 2023, time=2023-04-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2097725, encodeId=4d75209e7251f, content=偏重的研究方向：细胞增殖 经验分享：分值高的二区杂志，6个审稿人给了一些不痛不痒的小意见，没有拒稿，但是被编辑给拒了，垃圾。转投了其他一区杂志，接受了，因祸得福, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:34:30 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237083, encodeId=4a0b123e083bd, content=2.25 投稿，不知为何，5月才开始外审， 6.3通知Major revision，6.20修回，7.14通知Minor revision，7.26 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Sun Aug 07 13:58:40 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145106, encodeId=955021451062a, content=偏重的研究方向：肿瘤基础研究;干细胞;肿瘤生物学 经验分享：外审5个月，4个小修，编辑拒稿。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a28115392, createdName=ms3000000199710851, createdTime=Tue Jun 27 22:54:13 CST 2023, time=2023-06-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118154, encodeId=430721181541e, content=2月15号投稿，现在3月7号，还在awaiting reviewer assignment，发邮件没回应，托人问了华西的副主编，说帮忙看下，3天了也没动静，正在考虑转投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61698567057, createdName=ms5000001252099123, createdTime=Tue Mar 07 17:36:16 CST 2023, time=2023-03-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2100638, encodeId=36b12100638d0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：想请教大家目前的版面费多少？感觉好贵啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c35607832, createdName=ms8000000829948764, createdTime=Tue Nov 15 12:10:51 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077306, encodeId=049510e7306a2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：2021.11.30刚刚接受，分享一下，祝愿大家都顺利吧。 9月初投稿，10月中旬收到major revison，4个审稿人，1个非常正面，其他3个每人差不多提了4-5个问题，相对偏正面，但是对abstract，introduction和discussion部分提出了较多质疑。返修时勤勤恳恳对每个问题都进行了详细的解释和回答，一时无解的也都尽量完整回复。返回去后，好像又送到了第一轮的审稿人那里，其中3个表示满意。11月底看到状态变成Awaiting Editor Decision 再是好像Awaiting EIC desision，然后好像过两天就接收了。 投文章真的太不容易了，这一篇之前被 Theranostics 、EBioMedicine 、Journal of Cellular and Molecular Medicine、iscience、journal of translational medicine都拒了。。。。。。所以最后有了着落非常欣慰！ 最后再次祝愿大家发文章顺利！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fd2128416, createdName=1501fc32e8m, createdTime=Mon Dec 06 11:48:42 CST 2021, time=2021-12-06, status=1, ipAttribution=)]

2022-11-15 ms8000000829948764

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：细胞增殖
经验分享：想请教大家目前的版面费多少？感觉好贵啊

60 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2164556, encodeId=8cfe216455686, content=Initial Submission需要几天呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Tue Oct 24 09:32:14 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161348, encodeId=60cd21613489e, content=想请问一下各位前辈，字数上限4000，是包括abstract、introduction、methods、results、discussion、conclusion一共不超过4000么？我看已发表的文章里也不止这个字数啊。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9445432257, createdName=ms6000000598189015, createdTime=Sat Oct 07 15:17:00 CST 2023, time=2023-10-07, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2126690, encodeId=7b6a2126690ae, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：4个月接收，速度还行。稿费贵了点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82618491364, createdName=ms5000000525855900, createdTime=Tue Apr 18 10:22:45 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2129213, encodeId=28b421292133a, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：各位朋友们请问该期刊对于wb实验数据的要求是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d118655417, createdName=ms8000001126979725, createdTime=Sat Apr 29 10:32:13 CST 2023, time=2023-04-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2097725, encodeId=4d75209e7251f, content=偏重的研究方向：细胞增殖 经验分享：分值高的二区杂志，6个审稿人给了一些不痛不痒的小意见，没有拒稿，但是被编辑给拒了，垃圾。转投了其他一区杂志，接受了，因祸得福, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:34:30 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237083, encodeId=4a0b123e083bd, content=2.25 投稿，不知为何，5月才开始外审， 6.3通知Major revision，6.20修回，7.14通知Minor revision，7.26 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5f851664041, createdName=COCO-么么哒, createdTime=Sun Aug 07 13:58:40 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145106, encodeId=955021451062a, content=偏重的研究方向：肿瘤基础研究;干细胞;肿瘤生物学 经验分享：外审5个月，4个小修，编辑拒稿。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a28115392, createdName=ms3000000199710851, createdTime=Tue Jun 27 22:54:13 CST 2023, time=2023-06-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118154, encodeId=430721181541e, content=2月15号投稿，现在3月7号，还在awaiting reviewer assignment，发邮件没回应，托人问了华西的副主编，说帮忙看下，3天了也没动静，正在考虑转投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61698567057, createdName=ms5000001252099123, createdTime=Tue Mar 07 17:36:16 CST 2023, time=2023-03-07, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2100638, encodeId=36b12100638d0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：想请教大家目前的版面费多少？感觉好贵啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c35607832, createdName=ms8000000829948764, createdTime=Tue Nov 15 12:10:51 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077306, encodeId=049510e7306a2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：细胞增殖 经验分享：2021.11.30刚刚接受，分享一下，祝愿大家都顺利吧。 9月初投稿，10月中旬收到major revison，4个审稿人，1个非常正面，其他3个每人差不多提了4-5个问题，相对偏正面，但是对abstract，introduction和discussion部分提出了较多质疑。返修时勤勤恳恳对每个问题都进行了详细的解释和回答，一时无解的也都尽量完整回复。返回去后，好像又送到了第一轮的审稿人那里，其中3个表示满意。11月底看到状态变成Awaiting Editor Decision 再是好像Awaiting EIC desision，然后好像过两天就接收了。 投文章真的太不容易了，这一篇之前被 Theranostics 、EBioMedicine 、Journal of Cellular and Molecular Medicine、iscience、journal of translational medicine都拒了。。。。。。所以最后有了着落非常欣慰！ 最后再次祝愿大家发文章顺利！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fd2128416, createdName=1501fc32e8m, createdTime=Mon Dec 06 11:48:42 CST 2021, time=2021-12-06, status=1, ipAttribution=)]

2021-12-06 1501fc32e8m

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：细胞增殖
经验分享：2021.11.30刚刚接受，分享一下，祝愿大家都顺利吧。
9月初投稿，10月中旬收到major revison，4个审稿人，1个非常正面，其他3个每人差不多提了4-5个问题，相对偏正面，但是对abstract，introduction和discussion部分提出了较多质疑。返修时勤勤恳恳对每个问题都进行了详细的解释和回答，一时无解的也都尽量完整回复。返回去后，好像又送到了第一轮的审稿人那里，其中3个表示满意。11月底看到状态变成Awaiting Editor Decision 再是好像Awaiting EIC desision，然后好像过两天就接收了。
投文章真的太不容易了，这一篇之前被 Theranostics 、EBioMedicine 、Journal of Cellular and Molecular Medicine、iscience、journal of translational medicine都拒了。。。。。。所以最后有了着落非常欣慰！
最后再次祝愿大家发文章顺利！！！

243 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务